BA
NAGE

BlackRock Advisors’s Niagen Bioscience NAGE Stock Holding History

BlackRock Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$30K Buy
8,956
+675
+8% +$1.83K ﹤0.01% 3372
2016
Q3 		$25K Hold
8,281
– – ﹤0.01% 3404
2016
Q2 		$34K Buy
+8,281
New +$39.2K ﹤0.01% 3327

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

BlackRock Advisors's NAGE Position: Q4 2016 in Review

BlackRock Advisors increased its Niagen Bioscience (NAGE) stake by 8.2% in Q4 2016, buying an estimated $1.83K and bringing the position to 8,956 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #3372.

BlackRock Advisors first reported a position in NAGE in Q2 2016 and has held it in 3 quarters since. The position peaked at $34K in Q2 2016. 52 funds tracked by Wall St. Rank hold NAGE as of Q4 2016.

  • BlackRock Advisors held 8,956 shares of Niagen Bioscience worth $30K as of Q4 2016.
  • BlackRock Advisors bought 675 Niagen Bioscience shares in Q4 2016, an estimated $1.83K.
  • Niagen Bioscience made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3372 holding.
  • BlackRock Advisors first reported a position in Niagen Bioscience in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Advisors's Niagen Bioscience position peaked at $34K in Q2 2016.
  • 52 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.